Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : health care related stocks -- Ignore unavailable to you. Want to Upgrade?

To: rowrowrow who wrote (4)	9/9/1999 9:39:00 PM
From: mark collins	Respond to of 43

NMPS, here's the skinny. worth following and seeing if the gain in price will continue. Matritech, Inc. 100 Day Chart Stock Quote SEC Filings Recent News . . Based on NMPS closing price of $2.625 on 09/09/99 Percentage price change year-to-date 58.5% Percentage change, last 52 Weeks 110.0% Price/Earnings Ratio (last 4 quarters) NM Price/Sales Ratio (last 4 quarters) 34.4 Market Capitalization $49 million Comparison Groups Medical Devices: Diagnostic Testing StockTalk Subjects Matritech (NASDAQ - NMPS) Latest: 09/09/1999 Company Links WSRN QuickSource Report (Fundamental Data) Matritech develops, manufactures and markets innovative cancer diagnostic products based on its proprietary nuclear matrix protein ("NMP") technology. The nuclear matrix, a three dimensional protein framework within the nucleus of cells, plays a fundamental role in determining cell type by physically organizing the contents of the nucleus, including DNA. The Company has demonstrated that there are differences in the types and amounts of NMPs found in cancerous and normal tissue and believes the detection of such differences in NMPs provides important diagnostic information about cellular abnormalities, including cancer. Using its proprietary NMP technology and expertise, the Company is developing a series of non-invasive or minimally invasive cancer diagnostic tests for bladder, colorectal, prostate, cervical and breast cancer, among others, which the Company believes will be more accurate and allow for reduced treatment costs and a higher standard of patient care than currently available tests. Recent Quarter Results (Earnings Release: ???) Quarter Ending 06/30/96 09/30/96 12/31/96 03/31/97 06/30/97 09/30/97 12/31/97 03/31/98 Revenue (millions) 0.6 0.7 0.8 0.3 0.3 0.4 0.4 0.4 Net Income (millions) -1.4 -1.1 -1.2 -1.5 -2.1 -2.1 -1.7 -2.1 Net Profit Margin -224.4% -167.9% -156.2% -492.9% -821.7% -580.6% -452.2% -501.2% Shares Outstanding (millions) 16.0 16.0 16.0 16.0 16.9 18.5 18.6 18.6